These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 30613140)

  • 1. Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β
    Wittbrodt ET; Millette LA; Evans KA; Bonafede M; Tkacz J; Ferguson GT
    Int J Chron Obstruct Pulmon Dis; 2019; 14():101-114. PubMed ID: 30613140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
    Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients.
    Darbà J; Ramírez G; Sicras A; Francoli P; Torvinen S; Sánchez-de la Rosa R
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2335-45. PubMed ID: 26604733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA.
    Park HS; Yoon D; Lee HY; Ban GY; Wan Yau Ming S; Jie JLZ; Carter V; Hardjojo A; Van Boven JFM; Price DB
    Respirology; 2019 Oct; 24(10):972-979. PubMed ID: 31038269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does Changing Inhaler Device Impact Real-Life Asthma Outcomes? Clinical and Economic Evaluation.
    Rhee CK; van Boven JFM; Yau Ming SW; Park HY; Kim DK; Park HS; Ling JZJ; Yoo KH; Price DB
    J Allergy Clin Immunol Pract; 2019 Mar; 7(3):934-942. PubMed ID: 30292924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device.
    Dekhuijzen PNR; Batsiou M; Bjermer L; Bosnic-Anticevich S; Chrystyn H; Papi A; Rodríguez-Roisin R; Fletcher M; Wood L; Cifra A; Soriano JB; Price DB
    Respir Med; 2016 Nov; 120():54-63. PubMed ID: 27817816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Persistence to treatment by type of inhaler device in patients with asthma and chronic obstructive pulmonary disease].
    Sicras A; Ferrer V; Collar JM; Navarro R; Sáez M
    Semergen; 2017; 43(5):375-386. PubMed ID: 27425817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation.
    Müller V; Gálffy G; Eszes N; Losonczy G; Bizzi A; Nicolini G; Chrystyn H; Tamási L
    BMC Pulm Med; 2011 Jul; 11():40. PubMed ID: 21762500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
    Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
    Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers.
    Singer D; Bengtson LGS; Elliott C; Buikema AR; Franchino-Elder J
    Int J Chron Obstruct Pulmon Dis; 2020; 15():3239-3250. PubMed ID: 33324047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of switching asthma patients from a Fixed-Dose Combination (FDC) Inhaled Corticosteroid [ICS]/Long-Acting Beta Agonist [LABA] therapy delivered by Dry Powder Inhaler (DPI) to ICS/LABA delivered by pressurised Metered Dose Inhaler (pMDI).
    Al-Ahmad M; Webb D
    Respir Med; 2022 Apr; 194():106771. PubMed ID: 35180515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
    Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
    Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An innovative corticosteroid/long-acting β
    Usmani O; Roche N; Marshall J; Danagher H; Price D
    Expert Opin Drug Deliv; 2019 Dec; 16(12):1367-1380. PubMed ID: 31752560
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative Safety and Effectiveness of Inhaled Corticosteroid and Long-Acting β
    Chang TY; Chien JY; Wu CH; Dong YH; Lin FJ
    Chest; 2020 May; 157(5):1117-1129. PubMed ID: 31887282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching treatments in COPD: implications for costs and treatment adherence.
    Braido F; Lavorini F; Blasi F; Baiardini I; Canonica GW
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2601-8. PubMed ID: 26664108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
    Berger WE; Noonan MJ
    J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Costs and Healthcare Resource Utilization (HCRU) Using LAMA versus LABA/ICS at Treatment Initiation for COPD: Findings from CITRUS (Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea) Study.
    Choi KY; Kim HI; Rhee CK; Yoo KH; Park YB; Kim Y; Lee SE; Kim JA; Hwang YI
    Int J Chron Obstruct Pulmon Dis; 2024; 19():1661-1671. PubMed ID: 39050737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010.
    Tsai YH; Yang TM; Lin CM; Huang SY; Wen YW
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2787-2793. PubMed ID: 29026296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.